Search

El virus SARS-CoV-2 causante de la enfermedad COVID-19 es altamente contagioso y debido a que la propagación nosocomial ha sido bien documentada, se han implementado directrices que incluyen el uso de elementos de pro­tección personal (EPP) con el objetivo de minimizar el riesgo de contagio en el personal de la salud. Secundario al uso continuo, repetitivo y prolongado de estos dispositivos, se pueden desencadenar procesos inflamatorios cutáneos tales como: dermatitis de contacto, prurito o urticaria por presión, o exacerbar procesos inflamatorios preexistentes como dermatitis seborreica, acné, entre otros. Por lo anterior, la Asociación Colombiana de Derma­tología y Cirugía Dermatológica (AsoColDerma), en alianza con el Hospital Universitario Centro Dermatológico Federico Lleras Acosta, como ente asesor del Gobierno colombiano, nos permitimos hacer las siguientes recomen­daciones encaminadas a reducir el riesgo de lesiones cutáneas derivadas del uso de los equipos de protección personal. Estas recomendaciones son de orientación general para la práctica clínica, y el personal de la salud las debe se­guir de forma individualizada, de acuerdo con sus necesidades y con los recursos disponibles.

Background Esophageal strictures are the common gastrointestinal complications in patients with epidermolysis bullosa (EB) requiring dilation. There is limited information on the best type of intervention, outcomes, and predictors for re-stenosis. Objectives We aimed to investigate the frequency, clinical presentation of esophageal strictures in EB patients, and to ascertain the predictors of re-stenosis. Methods We conducted a retrospective, multicenter cohort study involving 7 specialized, international EB centers on patients who were 0 to 50 years of age. Descriptive statistics and hazard risks for re-stenosis were calculated. Results We identified 125 patients with 497 esophageal stricture episodes over a mean period of observation of 17 (standard deviation [SD] = 11.91) years. Dilations were attempted in 90.74% of episodes, using guided fluoroscopy 45.23%, retrograde endoscopy 33.04%, and antegrade endoscopy 19.07%. Successful dilation was accomplished in 99.33% of attempts. Patients experienced a median of 2 (interquartile range [IQR]: 1-7) stricture episodes with a median interval between dilations of 7 (IQR: 4-12) months. Predictors for re-stenosis included: number of strictures (2 vs 1 stricture: χ = 4.293, P = 0.038, hazard ratio [HR] = 1.294 (95% confidence interval [CI]: 1.014--1.652 and 3 vs 1 stricture:χ = 7.986, P = 0.005, HR = 1.785 [95% CI: 1.194, 2.667]) and a long (≥1 cm) segment stricture (χ = 4.599, P = 0.032, HR = 1.347 (95% CI: 1.026--1.769). Complications were more common with the endoscopic approach (8/86, antegrade endoscopy; 2 /149, retrograde endoscopy vs 2/204, fluoroscopy; χ = 17.39, P-value Conclusions We found excellent dilation outcomes irrespective of the dilation procedure; however, with higher complications in the endoscopic approach. Long (>1 cm) segment involvement and multiple locations were predictive of stricture reoccurrence.

Background Intralesional injection of Candida antigen appears to be an effective alternative for the treatment of warts. Aim To determine the efficacy and safety of this treatment. Methods We retrospectively reviewed records of all children who received intralesional injection of Candida antigen at our center from January 2008 to July 2013. Results From a total of 220 patients, 156 (70.9%) had a complete response, 37 (16.8%) had a partial response, and 27 (12.2%) had no improvement. An average of 2.73 treatments was needed. Forty-seven of the patients with more than one wart (21.3%) also noted at least partial resolution of untreated warts at distant sites. Twenty-seven of the 47 patients (57.4%) had complete resolution. All treated patients experienced some discomfort at the time of the injection, but no serious side effects were reported. Discussion We report our results using this approach in a large group of children. Conclusion Intralesional injection of Candida antigen is an effective and safe therapy for children with multiple and recalcitrant cutaneous warts.

The purpose of this study was to evaluate the use of intralesional propranolol injection in the management of small, noncomplicated infantile hemangiomas (IHs) located in areas of cosmetic concern. A prospective study was performed in six female infants with small, non-complicated IHs in areas of cosmetic concern. The parents had refused oral propranolol or the patients had no response to topical timolol or had relapsed after oral propranolol and the parents refused further systemic treatment. All six patients were treated with 1 mg/mL propranolol solution at a dose of 0.2 mL/cm(2). The size, color, and growth of the hemangiomas were monitored and recorded every 4 weeks. Treatment response was evaluated using a 5-point scale: much better (+2), better (+1), same (0), worse (-1), and much worse (-2). Heart rate and blood pressure were measured before and 1 hour after each injection. Adverse effects after medication were evaluated and managed accordingly. All hemangiomas stopped growing during therapy, but no significant changes in size or color were observed, even after repeated injections, and all patients were evaluated as 0 (same). One patient whose hemangioma stopped growing during treatment presented rebound growth after therapy cessation. No changes in heart rate or blood pressure were observed after intralesional propranolol injection. Adverse effects observed were pain and redness after injection. Intralesional propranolol seems safe but is not effective for the treatment of IH.

Introducción: la patología dermatológica es frecuente y el acceso a especialistas está limitado tanto en lugares remotos como en las grandes ciudades. El empleo de teledermatología permite el diagnóstico y el tratamiento oportuno. Objetivo: describir la frecuencia de acuerdo intra e interobservador entre la valo­ ración dermatológica de rutina (examen físico directo) y la de teledermatología asincrónica. Métodos: se realizó una prueba piloto previa implementación de la plataforma de teledermatología. Dos dermatólogos expertos valoraron 39 pacientes que consultaron por primera vez al servicio de dermatología del Hospital de San José, Bogotá DC. Emitieron su diagnóstico independiente para evaluar el acuerdo interobservador. La plataforma de telemedicina asincrónica se utilizó para presentar las fotografías de las lesiones dos meses después de la valoración clínica directa. En esta fase se describe el acuerdo intra e interobservador y el grado de satisfacción de los dermatólogos con la plataforma. Resultaáos: el acuerdo intraobservador del examen físico directo y el teledermatológico fue 51 y 59% (evaluadores 1 y 2), siendo mayor ante patología tumoral (68 y 74%). En el examen físico directo el acuerdo interobservador fue 64% y se reduce a 46% con telemedicina. Conclusiones: la frecuencia de acuerdo entre el examen dermatológico directo y el tele­ dermatológico fue aceptable y mejora ante patología tumoral. Estos resultados coinciden con lo descrito en la literatura en series mayores.